Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593682 · ClinicalTrials.gov registry record · Phase 4
The Role of Orexin in Human Panic Disorder
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT02593682: Completed Phase 4 study, sponsored by University of California, San Francisco.
NCT02593682 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 3 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02593682, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to provide some information (pilot data) about whether the study drug, suvorexant, (1) affects levels of orexin in people with panic disorder, and (2) is associated with decreased panic symptoms in response to a carbon dioxide (CO2) challenge.
Primary Outcome
Change in orexin levels from baseline to +1 min post-CO2 challenge
Interventions
- DRUG placebo
- DRUG suvorexant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-05 |
| Est. Completion | 2020-03-13 |
| Phase | Phase 4 |
What the finished NCT02593682 record still lists
NCT02593682 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT02593682 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02593682 about?
NCT02593682 is a clinical study titled "The Role of Orexin in Human Panic Disorder". The purpose of this study is to provide some information (pilot data) about whether the study drug, suvorexant, (1) affects levels of orexin in people with panic disorder, and (2) is associated with decreased panic symptoms in response to a carbon dioxide (CO2) challenge.
What is the current status of trial NCT02593682?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2016-05. Estimated completion is 2020-03-13.
What interventions are being tested in trial NCT02593682?
The interventions under investigation include: placebo (DRUG), suvorexant (DRUG).
Who is sponsoring clinical trial NCT02593682?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02593682's enrollment target sits among peer trials
3 1995th of 2000 higher than 3 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia